



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Myalepta

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
PSUSA/10700 /202401	Periodic Safety Update EU Single assessment - metreleptin	05/09/2024	n/a		PRAC Recommendation - maintenance
T/0038	Transfer of Marketing Authorisation	16/07/2024	29/07/2024	SmPC, Labelling and PL	
IA/0036	A.4 - Administrative change - Change in the name	25/03/2024	29/07/2024	Annex II	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
S/0035	5th annual re-assessment	25/01/2024	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Myalepta should be maintained.
N/0034	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	17/10/2023	29/07/2024	PL	
IB/0033/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	05/09/2023	n/a		
PSUSA/10700 /202301	Periodic Safety Update EU Single assessment - metreleptin	31/08/2023	n/a		PRAC Recommendation - maintenance
R/0031	Renewal of the marketing authorisation.	26/01/2023	31/03/2023	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Myalepta in the approved indication remains favourable, but recommended that one additional five-year renewal be

					<p>required based on the following pharmacovigilance grounds:</p> <p>There are three ongoing post-marketing studies (SOBs) which can provide additional information to better characterise the safety profile of metreleptin and have an impact on the benefit-risk balance of Myalepta. Therefore, a second renewal is required.</p>
S/0030	Annual re-assessment.	26/01/2023	n/a		
PSUSA/10700/202201	Periodic Safety Update EU Single assessment - metreleptin	01/09/2022	n/a		PRAC Recommendation - maintenance
II/0025	<p>Submission of an updated RMP (version 2.2) in order to introduce amendments to the protocol of efficacy and safety study (Specific Obligation SOB002 (AEGR-734-002)) to further investigate the effect of Myalepta on poor metabolic control once background therapy is maximized in patients with familial or acquired partial LD. The Annex IIE of the product information is updated to include a revised due date for submission of the final study report. Further, the MAH took the opportunity to update the RMP in line with the outcome of previous procedures and to include editorial changes.</p> <p>C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required</p>	21/07/2022	16/12/2022	Annex II	

IA/0029	A.7 - Administrative change - Deletion of manufacturing sites	13/07/2022	n/a		
IA/0028/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>	22/04/2022	n/a		
S/0023	Annual re-assessment.	24/03/2022	n/a		
IB/0026	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	02/02/2022	n/a		
IB/0024	B.II.f.z - Stability of FP - Other variation	18/11/2021	16/12/2022	SmPC, Annex II, Labelling	To update the shelf life of Myalepta from '36 months' to '48 months' in section 6.3 of the Summary of Product Characteristics (SmPC).

				and PL	To update Annex II and Package Leaflet of the Product Information with typographical and linguistic changes and in line with the current version of the QRD template.
PSUSA/10700/202101	Periodic Safety Update EU Single assessment - metreleptin	02/09/2021	n/a		PRAC Recommendation - maintenance
II/0020/G	<p>This was an application for a group of variations.</p> <p>C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority</p> <p>C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority</p>	02/09/2021	n/a		
IAIN/0022	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	05/08/2021	n/a		
II/0017/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS</p>	06/05/2021	n/a		

IB/0018	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	15/03/2021	n/a		
IA/0019/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites	04/03/2021	n/a		
PSUSA/10700 /202007	Periodic Safety Update EU Single assessment - metreleptin	11/02/2021	n/a		PRAC Recommendation - maintenance
S/0014	2nd annual re-assessment	28/01/2021	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Myalepta should be maintained.
IAIN/0016/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.7 - Administrative change - Deletion of manufacturing sites	26/11/2020	15/11/2021	SmPC, Annex II, Labelling and PL	
II/0012	Update of section 4.4 of the SmPC in order to add a new warning on the risk of autoimmune disease following exposure to metreleptin; the Package	01/10/2020	15/11/2021	SmPC, Annex II and PL	Autoimmune disorder progression and flares, including severe autoimmune hepatitis, have been observed in some patients treated with metreleptin. Even though a clear

	<p>Leaflet and the key elements to be included in the Guide/training material for healthcare professionals are updated accordingly. The RMP version 2.0 has also been submitted.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				<p>causal relationship between metreleptin and progression of autoimmune disease has not been established it is recommended to closely monitor treated patients for underlying autoimmune disorder flares.</p> <p>For more information, please refer to the Summary of Product Characteristics.</p>
PSUSA/10700 /202001	Periodic Safety Update EU Single assessment - metreleptin	03/09/2020	n/a		PRAC Recommendation - maintenance
T/0011	Transfer of Marketing Authorisation	17/01/2020	28/04/2020	SmPC, Labelling and PL	
S/0009	Annual re-assessment.	26/03/2020	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Myalepta should be maintained.
PSUSA/10700 /201907	Periodic Safety Update EU Single assessment - metreleptin	13/02/2020	n/a		PRAC Recommendation - maintenance
IB/0008/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure</p>	25/09/2019	n/a		

	(including replacement or addition) B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product				
PSUSA/10700 /201901	Periodic Safety Update EU Single assessment - metreleptin	05/09/2019	n/a		PRAC Recommendation - maintenance
IB/0007	B.I.c.1.z - Change in immediate packaging of the AS - Other variation	26/08/2019	n/a		
II/0004	B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	20/06/2019	n/a		
IAIN/0005	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	26/03/2019	23/09/2019	Annex II and PL	
II/0003	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	13/12/2018	n/a		

IB/0002	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	30/11/2018	n/a		
IB/0001/G	<p>This was an application for a group of variations.</p> <p>B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product</p> <p>B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p>	04/10/2018	23/09/2019	SmPC, Labelling and PL	